Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The IGHMBP2 cryptic splice site variant c.1235+894C>A is a deep intronic mutation located within intron 8 of the Immunoglobulin mu-binding protein 2 (IGHMBP2) gene (Saladini et al., 2022). This mutation creates a de novo 5' donor splice site, which leads to the inclusion of a 65-base pair pseudoexon into the mature mRNA transcript, causing a frameshift and a premature termination codon (Nizzardo et al., 2015). The resulting loss of functional IGHMBP2 protein, an ATP-dependent helicase involved in DNA replication and RNA processing, leads to Spinal Muscular Atrophy with Respiratory Distress type 1 (SMARD1), a severe autosomal recessive motor neuron disease (Corti et al., 2012). This cryptic splice site serves as a therapeutic target for splice-switching antisense oligonucleotides (ASOs) designed to sterically block the recognition of the mutation by the spliceosome, thereby restoring normal splicing (Saladini et al., 2022). By preventing pseudoexon inclusion, these ASOs aim to increase the production of full-length, functional IGHMBP2 protein and alleviate the disease phenotype. Experimental studies in mouse models have demonstrated that targeting this specific variant can improve motor function and extend survival (Saladini et al., 2022).
Splice-switching to mask cryptic splice sites and restore canonical mRNA processing
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin mu-binding protein 2 (IGHMBP2) pre-mRNA cryptic splice site variant c.1235+894C>A (IGHMBP2 c.1235+894C>A).